Sai Life Sciences Ltd

Sai Life Sciences Ltd has announced that its Board of Directors will convene on August 6, 2026, to consider and approve the Un-audited Financial Results for the quarter ended June 30, 2026. The results will include both standalone and consolidated figures. Concurrently, the company has closed its trading window from July 1, 2026, to August 8, 2026, for directors, officials, and designated persons to prevent insider trading.

Sai Life Sciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. The window will be closed from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the first quarter ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. Insiders are prohibited from trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.

Sai Life Sciences Ltd has released the Monitoring Agency Report for the quarter and year ended March 31, 2026, as per Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, issued by CRISIL Ratings Limited, monitors the utilization of IPO proceeds. The report indicates no deviations from the IPO's stated objectives. As of March 31, 2026, ₹345.88 million has been spent out of the ₹401.16 million allocated for issue expenses, with the remaining ₹55.28 million parked in fixed deposits and a public offer account.

Sai Life Sciences Ltd's audited financial results for the year ended March 31, 2026, reveal a revenue from operations of ₹21,532.26 million, compared to ₹16,420.48 million in the previous year. The company's net profit for the year stood at ₹3,414.81 million, up from ₹1,734.62 million in FY25. The Board of Directors approved these results at a meeting held on May 14, 2026. Total assets increased from ₹31,366.63 million in FY25 to ₹36,028.16 million in FY26.

Sai Life Sciences Ltd. announced its audited financial results for the year ended March 31, 2026. The Board of Directors approved the standalone and consolidated financial results in a meeting held on May 14, 2026. Revenue from operations for FY26 stood at ₹21,532.26 million compared to ₹16,420.48 million in FY25. The company's profit for the year was ₹3,414.81 million, up from ₹1,734.62 million in the previous year. Basic earnings per share increased to ₹16.27 from ₹9.00.

Sai Life Sciences announced that its Bidar campus, including Unit IV and Unit VI, now operates entirely on renewable power, making it the first Indian CRDMO site to achieve this milestone. The transition was achieved through a phased approach, utilizing solar and wind power via Open Access agreements and International Renewable Energy Certificates. Nearly 80% of Sai Life Sciences' total electricity consumption is now from renewable sources, resulting in zero market-based Scope 2 emissions and avoiding 35,110 metric tonnes of CO₂ emissions annually.

Sai Life Sciences Ltd received an order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi, demanding ₹16.28 Cr in IGST, ₹13.31 Cr in interest, and ₹3.25 Cr in penalty under the Goods and Services Tax Act, 2017. The demand relates to alleged excess availment of Input Tax Credit for FY2021-22. Sai Life Sciences plans to appeal the order and anticipates a favorable outcome, expecting no material financial impact on the company.

Sai Life Sciences Ltd has announced that its Board of Directors will convene a meeting on Thursday, May 14, 2026. The primary agenda for this meeting is to consider and approve the Audited Financial Results (Standalone and Consolidated) for the fourth quarter and the full financial year ended March 31, 2026. In accordance with SEBI regulations, the trading window for dealing in the company's securities by designated persons and their immediate relatives has been closed from April 1, 2026, and will remain closed until 48 hours after the declaration of these financial results.

Sai Life Sciences Ltd has appointed Dr. John Pavey as a Senior Management Personnel, replacing Dr. Dean David Edney who is retiring. Dr. Pavey brings over two decades of global experience in CMC and chemical development. The appointment will take effect from 1 April 2026.

Sai Life Sciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The closure will be effective from Wednesday, 1st April, 2026 and will reopen after 48 hours from the declaration of the company's Audited Financial Results for the fourth quarter and year ending on March 31, 2026. The date of the Board Meeting to consider and approve the Audited Financial Results will be intimated to the Stock Exchanges in due course of time.